Distinguished in Cutaneous T-Cell Lymphoma (CTCL)

Dr. Ahmad S. Halwani

Oncology | Allergy and Immunology
University Of Utah Adult Services
1950 Circle Of Hope Dr, 
Salt Lake City, UT 
Accepting New Patients
Distinguished in Cutaneous T-Cell Lymphoma (CTCL)
University Of Utah Adult Services
1950 Circle Of Hope Dr, 
Salt Lake City, UT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ahmad Halwani is an Oncologist and an Allergy and Immunologist in Salt Lake City, Utah. Dr. Halwani is rated as a Distinguished provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). His top areas of expertise are Cutaneous T-Cell Lymphoma (CTCL), Follicular Lymphoma, T-Cell Lymphoma, Chronic B-Cell Leukemia (CBCL), and Bone Marrow Aspiration. Dr. Halwani is currently accepting new patients.

His clinical research consists of co-authoring 47 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 7 articles and participated in 1 clinical trial in the study of Cutaneous T-Cell Lymphoma (CTCL).

Specialties
Oncology
Allergy and Immunology
Licenses
Internal Medicine in IA
Hospital Affiliations
University Of Utah Hospital And Clinics
Languages Spoken
English
Arabic
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Deseret Mutual Benefit Administrators
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
EMI Health
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Regence
  • EPO
  • PPO
SelectHealth
  • HMO
  • POS
Steward Health Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Utah Health
  • EPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

UNIVERSITY OF UTAH ADULT SERVICES
1950 Circle Of Hope Dr, Salt Lake City, UT 84112

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Phase I Study Utilizing Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor Nivolumab for Relapsed/Refractory Lymphoma
Phase I Study Utilizing Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor Nivolumab for Relapsed/Refractory Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2025
Intervention Type: Drug, Biological
Study Drugs: TAA-T cells, Nivolumab
Study Phase: Phase 1
A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias
A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias
Enrollment Status: Completed
Publish Date: November 23, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: August 13, 2018
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Terminated
Publish Date: June 21, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

47 Total Publications

Using Open-Source Large Language Models to Identify Access to Germline Genetic Testing in Veterans With Breast Cancer From Unstructured Text.
Using Open-Source Large Language Models to Identify Access to Germline Genetic Testing in Veterans With Breast Cancer From Unstructured Text.
Journal: JCO clinical cancer informatics
Published: July 22, 2025
Similar Doctors
Experienced in Cutaneous T-Cell Lymphoma (CTCL)
Dr. Belisario A. Arango
Hematology Oncology | Hematology | Oncology
Experienced in Cutaneous T-Cell Lymphoma (CTCL)
Dr. Belisario A. Arango
Hematology Oncology | Hematology | Oncology

Utah Cancer Specialists PC

Ogden, UT 
 (27.3 miles away)
385-423-2855
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Belisario Arango is a Hematologist Oncology specialist and a Hematologist in Ogden, Utah. Dr. Arango is rated as an Advanced provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). His top areas of expertise are Inflammatory Breast Cancer, Breast Cancer, Paget Disease of the Breast, and Hemochromatosis. Dr. Arango is currently accepting new patients.

Experienced in Cutaneous T-Cell Lymphoma (CTCL)
Dr. Brian L. Mcclune
Hematology Oncology | Hematology | Oncology
Experienced in Cutaneous T-Cell Lymphoma (CTCL)
Dr. Brian L. Mcclune
Hematology Oncology | Hematology | Oncology

University Of Utah Adult Services

1950 Circle Of Hope Dr, 
Salt Lake City, UT 
 (0.1 miles away)
801-581-8793
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Brian Mcclune is a Hematologist Oncology specialist and a Hematologist in Salt Lake City, Utah. Dr. Mcclune is rated as a Distinguished provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). His top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia with Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Mcclune is currently accepting new patients.

Experienced in Cutaneous T-Cell Lymphoma (CTCL)
Dr. Carl R. Gray
Hematology Oncology | Hematology | Oncology
Experienced in Cutaneous T-Cell Lymphoma (CTCL)
Dr. Carl R. Gray
Hematology Oncology | Hematology | Oncology

Ogden Clinic Specialty Services LLC

Ogden, UT 
 (27.3 miles away)
801-476-1777
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Carl Gray is a Hematologist Oncology specialist and a Hematologist in Ogden, Utah. Dr. Gray is rated as a Distinguished provider by MediFind in the treatment of Cutaneous T-Cell Lymphoma (CTCL). His top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Breast Cancer, Childhood Iron Deficiency Anemia, and Paget Disease of the Breast. Dr. Gray is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Halwani's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 21 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile